MetaVia Inc. (Nasdaq: MTVA) announced on November 17, 2026, that the last patient has completed the final study visit for its Phase 1 clinical trial evaluating DA-1726, a dual-receptor agonist. The company elected to extend the treatment period from 16 to 24 weeks, with patients receiving 48 mg of DA-1726 weekly for an additional eight weeks.

The company previously released data from Part 3B of the trial, which demonstrated a statistically significant 68.1% placebo-adjusted reduction in liver fat. This reduction was measured by MRI-PDFF, with all five DA-1726-treated participants who had liver steatosis at baseline achieving an MRI-PDFF below 5% by Day 109. The trial also showed a 13.5% placebo-adjusted reduction in body weight and improvements in glycemic control.

MetaVia stated that the encouraging preliminary safety and tolerability observations in Part 3A supported the decision to extend the treatment duration. The company plans to report the full data from Parts 3A and 3B in the first quarter of 2027. Based on these results, the company is preparing to initiate a 48-week, non-biopsy Phase 2 study in up to 150 patients with metabolic dysfunction and alcohol-associated liver disease (MetALD) and alcohol-associated liver disease (ALD), targeting a start date in the second half of 2027.